Identifying which patients should receive which therapy for lung cancer

Keith Kerr, MB, ChB, FRCPath, FRCPE from the University of Aberdeen, Aberdeen, Scotland gives an overview of his talk on histological and molecular profiling challenges in lung cancer held at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. Dr Kerr explains the importance of identifying which patients should receive which therapy.
Share this video